Search / Trial NCT00000234

Alternate Day Buprenorphine Administration, Phase XI - 16

Launched by UNIVERSITY OF VERMONT · Sep 20, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Please contact site for information.

Trial Officials

Warren Bickel, Ph.D.

Principal Investigator

University of Vermont

About University Of Vermont

The University of Vermont (UVM) is a leading academic institution known for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UVM leverages its diverse expertise in medicine, public health, and biomedical sciences to conduct cutting-edge clinical studies. The university aims to translate scientific findings into effective treatments and interventions, ultimately improving patient outcomes and contributing to the broader medical community. UVM's research facilities and access to a wide patient population support its mission to foster a culture of inquiry and excellence in clinical research.

Locations

Burlington, Vermont, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials